<p>Highland Capital Management LLC 在第二季度减持了 Jazz Pharmaceuticals plc（纳斯达克股票代码：JAZZ - 免费报告）的持股比例，根据该公司最近向证券交易委员会提交的 13F 申报。该基金在本季度卖出 2,480 股后，持有这家专业制药公司的股票 29,990 股。Highland Capital Management LLC 在最新的提交给证券交易委员会的申报中，持有的 Jazz Pharmaceuticals 股份价值 3,201,000 美元。</p>
<p>获取 Jazz Pharmaceuticals 的警报：</p>
<ul>
<li>Zymeworks 为不仅仅是长期投资者带来希望</li>
</ul>
<p>一些其他对冲基金最近也调整了他们对 JAZZ 的持股。Rise Advisors LLC 在第一季度将其在 Jazz Pharmaceuticals 的持仓增加了 2,255.6%。Rise Advisors LLC 现在拥有 212 股这家专业制药公司的股票，价值 26,000 美元，在该期间又增持了 203 股。Versant Capital Management Inc 在第二季度增加了其在 Jazz Pharmaceuticals 的持股量 13,450.0%。Versant Capital Management Inc 现在拥有 271 股这家专业制药公司的股票，价值 29,000 美元，在上个季度购入了 269 股。GAMMA Investing LLC 在第二季度增加了其在 Jazz Pharmaceuticals 的持股 65.5%。GAMMA Investing LLC 现在拥有 293 股这家专业制药公司的股票，价值 31,000 美元，在该期间购入了 116 股。Gladius Capital Management LP 在第二季度购入了 Jazz Pharmaceuticals 的新股份，价值约 33,000 美元。最后，Cape Investment Advisory Inc.在第四季度将其在 Jazz Pharmaceuticals 的持股增加了 14,600.0%。Cape Investment Advisory Inc.现在拥有 294 股这家专业制药公司的股票，价值 36,000 美元，在该期间购入了 292 股。对冲基金和其他机构投资者拥有公司股份的 89.14%。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师对这支股票发表了意见。加拿大皇家银行将 Jazz Pharmaceuticals 的目标股价从 175.00 美元降至 174.00 美元，并为该公司设定了 “表现优异” 的评级，日期为 2019 年 8 月 1 日。康泰菲兹杰拉德重申了对 Jazz Pharmaceuticals 的 “超重” 评级，并在 2019 年 8 月 1 日的一份报告中给出了 140.00 美元的价格目标。StockNews.com 将 Jazz Pharmaceuticals 的股票评级从 “买入” 提升为 “强烈买入”，日期为 2019 年 8 月 1 日。摩根大通将 Jazz Pharmaceuticals 的目标股价从 190.00 美元提高至 202.00 美元，并在 2019 年 8 月 19 日的一份研究报告中给予该公司 “超重” 评级。最后，HC Wainwright 重申了对 Jazz Pharmaceuticals 的 “买入” 评级，并设定了 200.00 美元的价格目标，日期为 2019 年 8 月 1 日。四位股票研究分析师对该股票进行了持有评级，十一位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的一致评级为 “中等买入”，目标股价为 173.07 美元。</p>
<p>查看我们对 JAZZ 的最新股票分析</p>
<h2>Jazz Pharmaceuticals 股票表现</h2>
<p>JAZZ 股票周一开盘价为 114.73 美元。该股票的 50 天移动平均价格为 109.11 美元，200 天移动平均价格为 112.99 美元。该公司的资产负债比为 1.36，速动比率为 1.90，流动比率为 2.37。Jazz Pharmaceuticals plc 的一年最低价为 99.06 美元，一年最高价为 146.70 美元。该公司的市值为 72.4 亿美元，市盈率为 23.48，PEG 比为 1.76，贝塔系数为 0.58。</p>
<h2>Jazz Pharmaceuticals 简介（免费报告）</h2>
<p>Jazz Pharmaceuticals plc 在美国、欧洲和国际市场确定、开发和销售满足医疗需求的药品。该公司提供 Xywav 用于猝倒或白天过度嗜睡（EDS）伴有睡病和特发性嗜睡症；Xyrem 用于治疗猝倒或白天过度嗜睡伴有睡病；Epidiolex 用于与 Lennox-Gastaut 综合征、Dravet 综合征或结节硬化复杂相关的癫痫发作；Zepzelca 用于治疗转移性小细胞肺癌，或在铂类化疗后疾病进展；Rylaze 用于急性淋巴细胞白血病或淋巴细胞淋巴瘤；Enrylaze 用于治疗急性淋巴细胞白血病和淋巴细胞淋巴瘤；Defitelio 用于治疗严重肝静脉闭塞性疾病；Vyxeos 用于新诊断的治疗相关急性髓系白血病。</p>
<h2>进一步阅读</h2>
<ul>
<li>五支我们比 Jazz Pharmaceuticals 更喜欢的股票</li>
<li>房地产投资信托股票 - 今天添加到您的投资组合的最佳房地产投资信托股票</li>
<li>艾礼礼制药通往下一个万亿市值之路</li>
<li>在 52 周最低点找到并有利可图地交易股票</li>
<li>Mobileye Global：首席执行官对未来实力进行 1000 万美元的押注</li>
<li>上海证券交易所综合指数是什么？</li>
<li>3 支在降息之前增加股息支付的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 唯一值得购买的人工智能公司（由波特和公司提供）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Jazz Pharmaceuticals 股票？</h2>
<p>在考虑购买 Jazz Pharmaceuticals 股票之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后再更广泛市场关注之前...而爵士制药并不在这份名单上。</p>
<p>尽管爵士制药目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

爵士制药

<p>高原资本管理有限责任公司在第二季度减持了爵士制药（Jazz Pharmaceuticals plc，NASDAQ: JAZZ）的股份，根据最近的 13F 申报，减持了 7.6%。在出售了 2,480 股后，他们现在持有 29,990 股，价值 201,000 美元。其他对冲基金也调整了他们的持股，显示出对爵士制药周围有显着的活动。分析师对该股的评级褒贬不一，但共识仍然是 “中度买入”，目标价为 118.07 美元。该股的表现显示市值为 62.4 亿美元，在过去一年内的交易价格介于 54.06 美元和 70.70 美元之间</p>

<p>Highland Capital Management LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,990 shares of the specialty pharmaceutical company's stock after selling 2,480 shares during the quarter. Highland Capital Management LLC's holdings in Jazz Pharmaceuticals were worth $3,201,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Highland Capital Management LLC 在第二季度减持了 Jazz Pharmaceuticals plc（纳斯达克股票代码：JAZZ - 免费报告）的持股比例，根据该公司最近向证券交易委员会提交的 13F 申报。该基金在本季度卖出 2,480 股后，持有这家专业制药公司的股票 29,990 股。Highland Capital Management LLC 在最新的提交给证券交易委员会的申报中，持有的 Jazz Pharmaceuticals 股份价值 3,201,000 美元。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><p>获取 Jazz Pharmaceuticals 的警报：</p>
<ul>
<li>Zymeworks 为不仅仅是长期投资者带来希望</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after buying an additional 292 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>一些其他对冲基金最近也调整了他们对 JAZZ 的持股。Rise Advisors LLC 在第一季度将其在 Jazz Pharmaceuticals 的持仓增加了 2,255.6%。Rise Advisors LLC 现在拥有 212 股这家专业制药公司的股票，价值 26,000 美元，在该期间又增持了 203 股。Versant Capital Management Inc 在第二季度增加了其在 Jazz Pharmaceuticals 的持股量 13,450.0%。Versant Capital Management Inc 现在拥有 271 股这家专业制药公司的股票，价值 29,000 美元，在上个季度购入了 269 股。GAMMA Investing LLC 在第二季度增加了其在 Jazz Pharmaceuticals 的持股 65.5%。GAMMA Investing LLC 现在拥有 293 股这家专业制药公司的股票，价值 31,000 美元，在该期间购入了 116 股。Gladius Capital Management LP 在第二季度购入了 Jazz Pharmaceuticals 的新股份，价值约 33,000 美元。最后，Cape Investment Advisory Inc.在第四季度将其在 Jazz Pharmaceuticals 的持股增加了 14,600.0%。Cape Investment Advisory Inc.现在拥有 294 股这家专业制药公司的股票，价值 36,000 美元，在该期间购入了 292 股。对冲基金和其他机构投资者拥有公司股份的 89.14%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an &#34;outperform&#34; rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald restated an &#34;overweight&#34; rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 1st. JPMorgan Chase &amp; Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, August 19th. Finally, HC Wainwright restated a &#34;buy&#34; rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $173.07.</p>
<ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><p>一些研究分析师对这支股票发表了意见。加拿大皇家银行将 Jazz Pharmaceuticals 的目标股价从 175.00 美元降至 174.00 美元，并为该公司设定了 “表现优异” 的评级，日期为 2019 年 8 月 1 日。康泰菲兹杰拉德重申了对 Jazz Pharmaceuticals 的 “超重” 评级，并在 2019 年 8 月 1 日的一份报告中给出了 140.00 美元的价格目标。StockNews.com 将 Jazz Pharmaceuticals 的股票评级从 “买入” 提升为 “强烈买入”，日期为 2019 年 8 月 1 日。摩根大通将 Jazz Pharmaceuticals 的目标股价从 190.00 美元提高至 202.00 美元，并在 2019 年 8 月 19 日的一份研究报告中给予该公司 “超重” 评级。最后，HC Wainwright 重申了对 Jazz Pharmaceuticals 的 “买入” 评级，并设定了 200.00 美元的价格目标，日期为 2019 年 8 月 1 日。四位股票研究分析师对该股票进行了持有评级，十一位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的一致评级为 “中等买入”，目标股价为 173.07 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on JAZZ</strong></p>
<div class="lb-trans"><p>查看我们对 JAZZ 的最新股票分析</p>
</div><h2>Jazz Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票表现</h2>
</div><p>Shares of JAZZ stock opened at $114.73 on Monday. The stock's 50-day moving average is $109.11 and its two-hundred day moving average is $112.99. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $146.70. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58.</p>
<div class="lb-trans"><p>JAZZ 股票周一开盘价为 114.73 美元。该股票的 50 天移动平均价格为 109.11 美元，200 天移动平均价格为 112.99 美元。该公司的资产负债比为 1.36，速动比率为 1.90，流动比率为 2.37。Jazz Pharmaceuticals plc 的一年最低价为 99.06 美元，一年最高价为 146.70 美元。该公司的市值为 72.4 亿美元，市盈率为 23.48，PEG 比为 1.76，贝塔系数为 0.58。</p>
</div><h2>Jazz Pharmaceuticals Profile (Free Report)</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 简介（免费报告）</h2>
</div><p>Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 在美国、欧洲和国际市场确定、开发和销售满足医疗需求的药品。该公司提供 Xywav 用于猝倒或白天过度嗜睡（EDS）伴有睡病和特发性嗜睡症；Xyrem 用于治疗猝倒或白天过度嗜睡伴有睡病；Epidiolex 用于与 Lennox-Gastaut 综合征、Dravet 综合征或结节硬化复杂相关的癫痫发作；Zepzelca 用于治疗转移性小细胞肺癌，或在铂类化疗后疾病进展；Rylaze 用于急性淋巴细胞白血病或淋巴细胞淋巴瘤；Enrylaze 用于治疗急性淋巴细胞白血病和淋巴细胞淋巴瘤；Defitelio 用于治疗严重肝静脉闭塞性疾病；Vyxeos 用于新诊断的治疗相关急性髓系白血病。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Eli Lilly’s Path to the Next Trillion Market Capitalization</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Mobileye Global: CEO Makes $10 Million Bet on Future Strength</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>五支我们比 Jazz Pharmaceuticals 更喜欢的股票</li>
<li>房地产投资信托股票 - 今天添加到您的投资组合的最佳房地产投资信托股票</li>
<li>艾礼礼制药通往下一个万亿市值之路</li>
<li>在 52 周最低点找到并有利可图地交易股票</li>
<li>Mobileye Global：首席执行官对未来实力进行 1000 万美元的押注</li>
<li>上海证券交易所综合指数是什么？</li>
<li>3 支在降息之前增加股息支付的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ The only AI company to buy (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 唯一值得购买的人工智能公司（由波特和公司提供）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8866&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Jazz Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Jazz Pharmaceuticals 股票？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Jazz Pharmaceuticals 股票之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后再更广泛市场关注之前...而爵士制药并不在这份名单上。</p>
</div><p>While Jazz Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管爵士制药目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Highland Capital Management LLC 减少了在爵士制药公司（NASDAQ:JAZZ）的持仓